Kedrion Biopharma participated with its own delegation of international guests at the International Primary Immunodeficiencies Congress (IPIC) held in Madrid, Spain from November 6 to 8, organized by the International Patient Organization for Primary Immunodeficiencies (IPOPI).
The objective of this Congress was to improve awareness and treatment of Primary Immunodeficiency Diseases (PIDs) and to promote scientific research and the importance of early diagnosis. To date, there are over 400 diseases identified as PIDs; rare genetic disorders causing the body's immune system to function improperly.
Among the topics addressed was the treatment of patients with Secondary Immunodeficiencies. Unlike PIDs, these diseases are acquired and can be caused by many extrinsic factors, including malignant tumors, metabolic diseases, malnutrition, aging, certain medications, radiation therapy and chemotherapy.
"The management of Secondary Deficiencies has become one of the most important topics of interest in recent years. Today it is of great importance and relevance to discuss and define a set of criteria in order to guide the decision to initiate and/or stop replacement therapy.” – said Antonio Pecoraro, Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II.- “A growing number of new drugs that selectively target B-cells are emerging as possible causes of Secondary antibody Deficiencies. The Conference has been credited with stimulating a serious reflection on Secondary Deficiencies among a wide audience of international experts in this field".
Kedrion has a longstanding partnership with IPOPI. Year after year, our collaborative journey has been enriched with new activities and projects aimed at improving the quality of life for all patients living Primary Immunodeficiency.
"The aim of this congress is to provide all attendees with an update on diagnosis and treatment in this field.” – said Martine Pergent, IPOPI Chairperson, – “Focusing on treatment is very important because patients need to see how new research is translated to the care they receive and how the outcomes of research impact their daily life. For this reason, IPIC is about that: the translation from research to patients".
